All Clarivate websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.
The sad phase III fate of Abbvie Inc.’s rovalpituzumab tesirine, also known as rova T, in advanced small-cell lung cancer (SCLC) has not discouraged other drug developers targeting delta-like ligand 3 (DLL3) – not all of them, anyway.